BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 22342785)

  • 1. A novel and accurate computer model of melanoma prognosis for patients staged by sentinel lymph node biopsy: comparison with the American Joint Committee on Cancer model.
    Callender GG; Gershenwald JE; Egger ME; Scoggins CR; Martin RC; Schacherer CW; Edwards MJ; Urist MM; Ross MI; Stromberg AJ; McMasters KM
    J Am Coll Surg; 2012 Apr; 214(4):608-17; discussion 617-9. PubMed ID: 22342785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
    Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
    J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. American Joint Committee on Cancer clinical stage as a selection criterion for sentinel lymph node biopsy in thin melanoma.
    Vaquerano J; Kraybill WG; Driscoll DL; Cheney R; Kane JM
    Ann Surg Oncol; 2006 Feb; 13(2):198-204. PubMed ID: 16418885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system.
    Wong SL; Kattan MW; McMasters KM; Coit DG
    Ann Surg Oncol; 2005 Apr; 12(4):282-8. PubMed ID: 15827679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma.
    Burton AL; Gilbert J; Farmer RW; Stromberg AJ; Hagendoorn L; Ross MI; Martin RC; McMasters KM; Scoggins CR; Callender GG
    Am Surg; 2011 Aug; 77(8):1009-13. PubMed ID: 21944515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection.
    Debarbieux S; Duru G; Dalle S; Béatrix O; Balme B; Thomas L
    Br J Dermatol; 2007 Jul; 157(1):58-67. PubMed ID: 17501957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
    Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
    Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
    Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
    Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma.
    Murali R; Haydu LE; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Thompson JF; Scolyer RA
    Ann Surg; 2012 Jan; 255(1):128-33. PubMed ID: 21975320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
    Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
    Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of metallothionein-overexpression with sentinel lymph node biopsy as prognostic factors in melanoma.
    Weinlich G; Topar G; Eisendle K; Fritsch PO; Zelger B
    J Eur Acad Dermatol Venereol; 2007 May; 21(5):669-77. PubMed ID: 17447982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma.
    Kruper LL; Spitz FR; Czerniecki BJ; Fraker DL; Blackwood-Chirchir A; Ming ME; Elder DE; Elenitsas R; Guerry D; Gimotty PA
    Cancer; 2006 Nov; 107(10):2436-45. PubMed ID: 17058288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma?
    Gajdos C; Griffith KA; Wong SL; Johnson TM; Chang AE; Cimmino VM; Lowe L; Bradford CR; Rees RS; Sabel MS
    Cancer; 2009 Dec; 115(24):5752-60. PubMed ID: 19827151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis.
    Roka F; Kittler H; Cauzig P; Hoeller C; Hinterhuber G; Wolff K; Pehamberger H; Diem E
    Br J Cancer; 2005 Feb; 92(4):662-7. PubMed ID: 15700039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sentinel node biopsy provides more accurate staging than elective lymph node dissection in patients with cutaneous melanoma.
    Doubrovsky A; De Wilt JH; Scolyer RA; McCarthy WH; Thompson JF
    Ann Surg Oncol; 2004 Sep; 11(9):829-36. PubMed ID: 15313732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors associated with sentinel lymph node positivity and effect of sentinel status on survival: an analysis of 1049 patients with cutaneous melanoma.
    Kunte C; Geimer T; Baumert J; Konz B; Volkenandt M; Flaig M; Ruzicka T; Berking C; Schmid-Wendtner MH
    Melanoma Res; 2010 Aug; 20(4):330-7. PubMed ID: 20526218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diversity of stage III melanoma in the era of sentinel lymph node biopsy.
    Egger ME; Callender GG; McMasters KM; Ross MI; Martin RC; Edwards MJ; Urist MM; Noyes RD; Sussman JJ; Reintgen DS; Stromberg AJ; Scoggins CR
    Ann Surg Oncol; 2013 Mar; 20(3):956-63. PubMed ID: 23064795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI).
    Testori A; De Salvo GL; Montesco MC; Trifirò G; Mocellin S; Landi G; Macripò G; Carcoforo P; Ricotti G; Giudice G; Picciotto F; Donner D; Di Filippo F; Soteldo J; Casara D; Schiavon M; Vecchiato A; Pasquali S; Baldini F; Mazzarol G; Rossi CR;
    Ann Surg Oncol; 2009 Jul; 16(7):2018-27. PubMed ID: 19132446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with false-negative sentinel lymph node biopsy in melanoma patients.
    Scoggins CR; Martin RC; Ross MI; Edwards MJ; Reintgen DS; Urist MM; Gershenwald JE; Sussman JJ; Dirk Noyes R; Goydos JS; Beitsch PD; Ariyan S; Stromberg AJ; Hagendoorn LJ; McMasters KM
    Ann Surg Oncol; 2010 Mar; 17(3):709-17. PubMed ID: 19967459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.
    Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
    Ann Surg Oncol; 2006 Dec; 13(12):1655-63. PubMed ID: 17016755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.